By Doug Macron

A letter sent in 2004 by officials at the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology to the University of Massachusetts indicates that RNAi intellectual property at the heart of an ongoing legal battle belongs to the Max Planck Institute and therefore should be viewed as a confirmation of the ownership of the disputed IP, attorneys for plaintiffs Max Planck and Alnylam Pharmaceuticals argued this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.